VIRTUAL PHYSIOLOGICAL HUMAN INSTITUTE FOR INTEGRATIVE BIOMEDICAL RESEARCH VZW

Their core work

The VPH Institute is a Belgium-based research organization dedicated to advancing in silico (computer-based) testing and simulation of medical devices and pharmaceuticals. They develop computational models that simulate how drugs and implantable devices behave in the human body, aiming to reduce reliance on animal testing and clinical trials. Their core mission is bridging the gap between virtual physiological human models and regulatory acceptance, working to establish standards that allow simulation data to support device and drug certification.

What they specialise in

How they've shifted over time

All three projects started in 2021, so there is limited temporal spread to observe a true evolution. However, the keyword shift suggests a move from broad foundational work (virtual physiological human, regulatory science) toward more applied and specific use cases — cardiovascular implantable devices, certification standards, and proof of validation. The trajectory points toward operationalizing in silico methods for real regulatory submissions rather than purely theoretical framework development.

They are moving from proving that in silico trials can work toward establishing the standards and validation pathways that regulators require for formal acceptance.

How they like to work

The VPH Institute operates exclusively as a participant, never as a coordinator, suggesting they contribute specialized expertise rather than managing entire project lifecycles. With 33 unique partners across 13 countries from just 3 projects, they work in large, diverse consortia — typical of ambitious health-digital research initiatives. This makes them an accessible partner: experienced in multi-partner coordination without competing for the lead role.

Despite only three projects, they have built a network of 33 partners across 13 countries, indicating participation in large European consortia with broad geographic diversity. Their network spans much of the EU, with no apparent concentration in a single region.

What sets them apart

The VPH Institute sits at a rare intersection: they are not a medical device company, not a hospital, and not a pure software lab — they are a dedicated research center for the science of simulating human physiology for regulatory purposes. This positions them uniquely as a neutral, expert intermediary between computational modellers, device manufacturers, pharma companies, and regulators. For anyone building a consortium around digital twins in healthcare or in silico certification, they bring both the technical depth and the regulatory science credibility that reviewers look for.

Highlights from their portfolio

• ISW
  Largest funding share (EUR 376,875) and broadest scope — aimed at lowering barriers to ubiquitous adoption of in silico trials across the entire health sector.
• SimCardioTest
  Bridges both drugs and devices in a single project, targeting in silico testing and certification for cardiac applications — a dual regulatory challenge.
• SIMCOR
  Focuses specifically on validation and standards for cardiovascular implantable devices, directly addressing what regulators need to accept simulation evidence.